贾纳斯激酶
医学
酪氨酸激酶
银屑病
托法替尼
JAK-STAT信号通路
癌症研究
激酶
受体酪氨酸激酶
白癜风
药理学
酪氨酸激酶抑制剂
蛋白质酪氨酸磷酸酶
免疫学
布鲁顿酪氨酸激酶
信号转导
蛋白激酶A
干扰素
塞库金单抗
蛋白激酶结构域
酪氨酸激酶2
药品
细胞因子
炎症
作者
David Aldo De Luca,Ioannis‐Alexios Koumprentziotis,Diamant Thaçi
标识
DOI:10.1007/s40257-026-01095-2
摘要
Tyrosine kinase 2 has emerged as a compelling therapeutic target in dermatology because of its central position within the interleukin IL-23/T-helper 17, interleukin-12/T-helper 1, and type I interferon signaling pathways that underlie many immune-mediated inflammatory skin diseases. Unlike conventional Janus kinase inhibitors, which bind the catalytic domain through ATP-competitive mechanisms, selective tyrosine kinase 2 inhibitors act allosterically on the regulatory pseudokinase (Janus kinase homology 2) domain, a distinction that confers a high degree of biochemical selectivity; whether this translates into a more favorable long-term safety profile has not been established in comparative clinical trials. Deucravacitinib is the first agent of this class approved for moderate-to-severe plaque psoriasis and, more recently, psoriatic arthritis, while several further selective inhibitors are advancing through clinical development. Among these, zasocitinib and envudeucitinib have demonstrated efficacy in phase II and phase III clinical trials, further supporting the therapeutic potential of selective tyrosine kinase 2 inhibition across immune-mediated skin diseases. Beyond psoriasis, encouraging signals have been reported across a range of conditions, including cutaneous lupus erythematosus, lichen planus, and lichen planopilaris, with ongoing investigation in vitiligo and hidradenitis suppurativa. Responses have, however, proved indication dependent rather than uniform, with limited or inconsistent benefit in localized pustular forms of psoriasis and alopecia areata. This review summarizes the biology of tyrosine kinase 2, the rationale for its selective inhibition, and the current therapeutic landscape with completed and ongoing clinical evidence, underscoring that clinical utility appears to track the cytokine biology driving each disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI